An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
Clinical trial NCT03444753 · TERMINATED
Trial details
- NCT number
- NCT03444753
- Sponsor
- Bristol-Myers Squibb
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-05
- Primary completion
- 2022-02-14
- Enrollment
- 82
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.